Literature DB >> 3539534

Control of 5-aminolevulinate synthase in animals.

B K May, I A Borthwick, G Srivastava, B A Pirola, W H Elliott.   

Abstract

The proposed mechanism by which hepatic ALV-synthase mitochondrial levels are regulated is outlined in Fig. 2. ALV-synthase catalyzes the first and rate-limiting step in the heme pathway and is normally present in low amounts. A cytosolic, regulatory free heme pool tightly controls the amount of ALV-synthase in two ways. In the primary mechanism of regulation, heme is proposed to inhibit the synthesis of ALV-synthase mRNA. Most likely this would be mediated through the action of specific heme-binding protein(s) which recognize regulatory control regions of the ALV-synthase gene. Gene activity therefore is significantly repressed most of the time. When there is an increased demand for heme by newly synthesized cellular hemoproteins, the free heme pool is reduced, leading to a derepression of ALV-synthase mRNA synthesis. Once the need for increased heme synthesis is satisfied, inhibitory heme levels build up again. When drugs such as phenobarbital are administered to animals, there is a rapid induction in the liver of both cytochrome P-450 and ALV-synthase. It is proposed that the heme pool governing ALV-synthase levels is lowered by the increased heme demand due to cytochrome P-450 apoprotein formation. The primary event in the drug induction of ALV-synthase is therefore the increased synthesis of cytochrome P-450 apoprotein. However, the mechanism by which this occurs is unknown, although drugs do increase the synthesis of mRNA for cytochrome P-450 (Fig. 2). (There is evidence that for the aromatic hydrocarbons a specific cytosolic receptor exists.) In the acute hepatic porphyria diseases, uncontrolled synthesis of hepatic ALV-synthase occurs. The various forms are characterized by reduced levels of one of the heme pathway enzymes other than ALV-synthase. Attacks of the disease are commonly precipitated by drugs which induce cytochrome P-450, and the uncontrolled accumulation of ALV-synthase which accompanies these attacks results from the combined action of the block in the heme pathway and the increased cytochrome P-450 levels. A major challenge which now exists is to understand at the molecular level how the genes for ALV-synthase and cytochrome P-450 are regulated in the liver and other tissues.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3539534     DOI: 10.1016/b978-0-12-152828-7.50008-1

Source DB:  PubMed          Journal:  Curr Top Cell Regul        ISSN: 0070-2137


  10 in total

Review 1.  5-Aminolevulinate synthase and the first step of heme biosynthesis.

Authors:  G C Ferreira; J Gong
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

2.  Cloning and characterization of the hemA region of the Bacillus subtilis chromosome.

Authors:  M Petricek; L Rutberg; I Schröder; L Hederstedt
Journal:  J Bacteriol       Date:  1990-05       Impact factor: 3.490

3.  Expression of 5-aminolaevulinate synthase and cytochrome P-450 mRNAs in chicken embryo hepatocytes in vivo and in culture. Effect of porphyrinogenic drugs and haem.

Authors:  J W Hamilton; W J Bement; P R Sinclair; J F Sinclair; K E Wetterhahn
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

Review 4.  Cytochrome P450 regulation: the interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal.

Authors:  Maria Almira Correia; Peter R Sinclair; Francesco De Matteis
Journal:  Drug Metab Rev       Date:  2010-09-23       Impact factor: 4.518

5.  The Bacillus subtilis hemAXCDBL gene cluster, which encodes enzymes of the biosynthetic pathway from glutamate to uroporphyrinogen III.

Authors:  M Hansson; L Rutberg; I Schröder; L Hederstedt
Journal:  J Bacteriol       Date:  1991-04       Impact factor: 3.490

6.  Synergistic effect of 2,2',4,4',5,5'-hexachlorobiphenyl and 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic porphyrin levels in the rat.

Authors:  A P van Birgelen; K M Fase; J van der Kolk; H Poiger; A Brouwer; W Seinen; M van den Berg
Journal:  Environ Health Perspect       Date:  1996-05       Impact factor: 9.031

7.  5-Aminolevulinate synthase is at 3p21 and thus not the primary defect in X-linked sideroblastic anemia.

Authors:  G R Sutherland; E Baker; D F Callen; V J Hyland; B K May; M J Bawden; H M Healy; I A Borthwick
Journal:  Am J Hum Genet       Date:  1988-09       Impact factor: 11.025

8.  delta-Aminolaevulinate synthase expression in muscle after contractions and recovery.

Authors:  M Takahashi; D T McCurdy; D A Essig; D A Hood
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

9.  Biphasic ordered induction of heme synthesis in differentiating murine erythroleukemia cells: role of erythroid 5-aminolevulinate synthase.

Authors:  H Lake-Bullock; H A Dailey
Journal:  Mol Cell Biol       Date:  1993-11       Impact factor: 4.272

10.  5-aminolevulinic acid (ALA) deficiency causes impaired glucose tolerance and insulin resistance coincident with an attenuation of mitochondrial function in aged mice.

Authors:  Shinichi Saitoh; Satoshi Okano; Hidekazu Nohara; Hiroshi Nakano; Nobuyuki Shirasawa; Akira Naito; Masayuki Yamamoto; Vincent P Kelly; Kiwamu Takahashi; Tohru Tanaka; Motowo Nakajima; Osamu Nakajima
Journal:  PLoS One       Date:  2018-01-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.